RxDoctor Payments Data

Umesh Mishra, MD

Cardiovascular Disease · Lancaster, PANPI 1386918779

Payments from drug & device makers

$18,749in general payments, 2019–2025

Across 78 payments — averaging $240.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • Astrazeneca UK Limited$7K
  • Novartis$541
  • Johnson & Johnson$395
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • Abbott$55
  • plus $342 from 14 others

What the payments were for

  • Food & beverage$1,397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,749 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,901
Medicare patients
1,574
Services billed
3,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$180,509
XareltoRivaroxaban136$117,987
EntrestoSacubitril/Valsartan11$20,795
MultaqDronedarone Hcl13$10,243
BrilintaTicagrelor15$8,652
Metoprolol Succinate382$4,178
Amiodarone Hcl66$2,879
Atorvastatin Calcium406$2,783
Flecainide Acetate72$2,432
Acebutolol Hcl21$2,138
Rosuvastatin Calcium112$1,743
Ezetimibe65$1,451
SotalolSotalol Hcl34$973
Metoprolol Tartrate202$970
Lisinopril127$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$180,509163 claims
Johnson & JohnsonXarelto$395$117,987136 claims
NovartisEntresto$541$20,79511 claims
Sanofi-aventis U.S. LLCMultaq$24$10,24313 claims
AstraZenecaBrilinta$10,670$8,65215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →